» Articles » PMID: 35679462

Developing and Validating a Mortality Prediction Model for ICH in ITP: a Nationwide Representative Multicenter Study

Abstract

Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide multicenter real-world study of ICH in adult ITP patients. According to data from 27 centers in China from 2005 to 2020, the mortality rate from ICH was 33.80% (48/142) in ITP adults. We identified risk factors by logistic univariate and multivariate logistic regression for 30-day mortality in a training cohort of 107 patients as follows: intraparenchymal hemorrhage (IPH), platelet count ≤10 × 109/L at ICH, a combination of serious infections, grade of preceding bleeding events, and Glasgow coma scale (GCS) level on admission. Accordingly, a prognostic model of 30-day mortality was developed based on the regression equation. Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a test cohort with 35 patients from 11 other centers was conducted. The areas under the receiver operating characteristic (ROC) curves for the internal and external validation were 0.954 (95% confidence interval [CI], 0.910-0.998) and 0.942 (95% CI, 0.871-1.014), respectively. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.

Citing Articles

Incorporating platelet-to-white blood cell ratio into survival prediction models for intracerebral hemorrhage: a nomogram approach.

Xu J, Wang X, Chen W, Tian M, You C Front Neurol. 2024; 15:1464216.

PMID: 39450047 PMC: 11499137. DOI: 10.3389/fneur.2024.1464216.


Can Machine Learning Assist in Diagnosis of Primary Immune Thrombocytopenia? A Feasibility Study.

Miah H, Kollias D, Pedone G, Provan D, Chen F Diagnostics (Basel). 2024; 14(13).

PMID: 39001244 PMC: 11240714. DOI: 10.3390/diagnostics14131352.


How we treat primary immune thrombocytopenia in adults.

Liu X, Hou Y, Hou M J Hematol Oncol. 2023; 16(1):4.

PMID: 36658588 PMC: 9850343. DOI: 10.1186/s13045-023-01401-z.

References
1.
Neunert C, Noroozi N, Norman G, Buchanan G, Goy J, Nazi I . Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014; 13(3):457-64. PMC: 4991942. DOI: 10.1111/jth.12813. View

2.
Melboucy-Belkhir S, Khellaf M, Augier A, Boubaya M, Levy V, Le Guenno G . Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol. 2016; 91(12):E499-E501. DOI: 10.1002/ajh.24529. View

3.
Keller T, Mairuhu A, de Kruif M, Klein S, Gerdes V, Ten Cate H . Infections and endothelial cells. Cardiovasc Res. 2003; 60(1):40-8. DOI: 10.1016/s0008-6363(03)00354-7. View

4.
Cooper N, Ghanima W . Immune Thrombocytopenia. N Engl J Med. 2019; 381(10):945-955. DOI: 10.1056/NEJMcp1810479. View

5.
Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel J . International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2009; 115(2):168-86. DOI: 10.1182/blood-2009-06-225565. View